INNOVATIVE APPROACHES TO SCREENING, PREVENTION, THERAPY OF PREECLAMPSIA AND ITS "ENDPOINTS" IN THE CONDITIONS OF THE FERGANA VALLEY

Abstract

Background: Preeclampsia (PE) remains a leading cause of maternal mortality in the densely populated Fergana Valley. Traditional management often focuses on symptomatic treatment in the late stages, failing to prevent severe "endpoints" such as eclampsia, HELLP syndrome, and long-term cardiovascular disease. This study aims to evaluate the efficacy of an innovative "Predict and Prevent" model adapted to the specific demographic and genetic characteristics of the local population. Methods: A prospective interventional study involving 400 pregnant women was conducted at the Andijan Regional Perinatal Center. The Innovation Group (n=200) underwent combined first-trimester screening (MAP, UtA-PI, PlGF) and received targeted prophylaxis (Aspirin 150mg + Calcium). The Control Group (n=200) received standard care based on risk factors alone. "Endpoints" were defined as early-onset PE, eclampsia, and neonatal morbidity. Results: The innovative screening model demonstrated a sensitivity of 89% for predicting early-onset PE, compared to 35% in the standard care group. Targeted prophylaxis reduced the incidence of preterm PE by 60% (p<0.001). Crucially, the incidence of severe endpoints (eclampsia/HELLP) was significantly lower in the Innovation Group (0.5% vs 4.5%). Conclusion: Shifting from reactive therapy to proactive first-trimester screening and prevention significantly improves perinatal outcomes in the Fergana Valley. Regional protocols must encompass not just pregnancy management but also the prevention of long-term cardiovascular "endpoints" in women with a history of PE.